Literature DB >> 22381440

Treatment failure after uterine artery embolization: prospective cohort study with multifactorial analysis of possible predictors of long-term outcome.

Christian Scheurig-Muenkler1, Clemens Koesters, Christian Grieser, Bernd Hamm, Thomas J Kroencke.   

Abstract

PURPOSE: To evaluate the impact of baseline characteristics and residual leiomyoma perfusion after uterine artery embolization (UAE) on clinical long-term outcome.
MATERIALS AND METHODS: One hundred fifteen patients underwent UAE. All patients were divided into three groups according to achieved infarction rate determined on contrast-enhanced magnetic resonance imaging within 48-72 h after UAE (I: 100%, n=60; II: 90-99%, n=32; and III: 0-89%, n=23). Treatment failure and subsequent re-interventions (surgery, repeat UAE) were assessed for each group and compared using Cox regression analysis (CRA) with respect to the following baseline variables: age, uterine and dominant fibroid volume, number of fibroids, location of largest fibroid, and clinical symptoms.
RESULTS: Long-term follow-up was completed after a median of 7.2 years (range 5.1-9.6) with a response rate of 84%. CRA revealed that patients in group III had a 22.2-fold higher risk (p<0.001) of treatment failure than patients in group I, whereas groups I and II did not differ significantly (p=0.578). For patients with bleeding-related symptoms only, CRA showed a 5.1-fold higher risk (p=0.025) of treatment failure than for patients with equally dominant bleeding- and bulk-related symptoms. A 40.5-fold higher likelihood (p<0.001) of treatment failure was observed for patients in group III with bleeding-related symptoms only compared to those in group I with combined bleeding- and bulk-related symptoms.
CONCLUSION: Incomplete fibroid infarction after UAE is strongly associated with the risk of experiencing treatment failure. Patients with bleeding-related complaints only face the highest likelihood of treatment failure if UAE results in less than 90% fibroid devascularization.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22381440     DOI: 10.1016/j.ejrad.2012.01.031

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Three-Dimensional Quantitative Assessment of Uterine Fibroid Response after Uterine Artery Embolization Using Contrast-Enhanced MR Imaging.

Authors:  Julius Chapiro; Rafael Duran; MingDe Lin; John D Werner; Zhijun Wang; Rüdiger Schernthaner; Lynn Jeanette Savic; Mark L Lessne; Jean-François Geschwind; Kelvin Hong
Journal:  J Vasc Interv Radiol       Date:  2015-01-28       Impact factor: 3.464

2.  Randomised Controlled Trial of Particles Used in Uterine fibRoid Embolisation (PURE): Non-Spherical Polyvinyl Alcohol Versus Calibrated Microspheres.

Authors:  Raj Das; Anita Wale; Seyed Ameli Renani; Lakshmi Ratnam; Leto Mailli; Joo-Young Chun; Sourav Das; Balpreet Duggal; Isaac Manyonda; Anna-Maria Belli
Journal:  Cardiovasc Intervent Radiol       Date:  2022-01-04       Impact factor: 2.740

3.  Diffusion-weighted MR imaging of uterine leiomyomas following uterine artery embolization.

Authors:  Olivier Sutter; Philippe Soyer; Eimad Shotar; Raphael Dautry; Youcef Guerrache; Vinciane Placé; Raluca Opréa; Aude Ricbourg; Olivier Le Dref; Mourad Boudiaf; Marc Sirol; Anthony Dohan
Journal:  Eur Radiol       Date:  2016-01-22       Impact factor: 5.315

4.  European Society of Urogenital Radiology (ESUR) Guidelines: MR Imaging of Leiomyomas.

Authors:  Rahel A Kubik-Huch; Michael Weston; Stephanie Nougaret; Henrik Leonhardt; Isabelle Thomassin-Naggara; Mariana Horta; Teresa Margarida Cunha; Cristina Maciel; Andrea Rockall; Rosemarie Forstner
Journal:  Eur Radiol       Date:  2018-02-28       Impact factor: 5.315

5.  Uterine artery embolization for leioyomas, ultrasonography and angiography aspects.

Authors:  I A Horhoianu; V V Horhoianu; D Joita; M Carstoiu; B Dorobat
Journal:  J Med Life       Date:  2012-12-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.